Daily Bulletin

Men's Weekly

.

Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant prostate cancer (mCRPC) in the US. Patient...

Read more: Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

Business News

What Designers Really Think About Your Current Marketing Collateral

Key Takeaways: Designers notice structure, typography, and colour choices before the content itself Consistency across all collateral strengthens brand recognition and builds trust Overly bu...

Daily Bulletin - avatar Daily Bulletin

How to Choose the Right Air Conditioner for Your Home or Business

In Australia’s climate, where summer heat can be intense and winter chills are felt in many regions, air conditioning has become more than just a luxury; it’s an essential part of comfortable living. ...

Daily Bulletin - avatar Daily Bulletin

Why Heavy Duty Moving Dollies Are Essential for Safe Transport in Australia

Moving heavy or bulky items can be challenging, especially when it involves transporting goods across warehouses, offices, or even during residential relocations. In Australia, where industries like c...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals